Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Hypercholesterolemia: HELP
Michel Farnier
Based on 24 articles published since 2008
||||
Expertise Level
The expertise of Michel Farnier ranks in the
  • Top 0.1%
  • ... of 27,988 published authors worldwide on Hypercholesterolemia
  • ... from 2008 through 2018
  • ... based on contributions to 24 articles on the topic.
Graphical view (beta)
Uncounted papers?
Get your prestigious
Expert badge
similar to this:
 
Aliases Farnier, M   ·   Farnier, Michel
Work Locations
Details
Most likely:    Miscellaneous institutions in Dijon      
2017
  • University of Iowa, Iowa City, Iowa. Electronic address: · Icahn School of Medicine at Mount Sinai, New York, New York. · Point Médical, Dijon, France. · Sanofi, Bridgewater, New Jersey. · Regeneron Pharmaceuticals, Inc., Tarrytown, New York. · Sanofi, Chilly-Mazarin, France. · Regeneron Pharmaceuticals, Inc., Basking Ridge, New Jersey. · Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. · Pubmed 28153102
2016
  • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands · Duke University Medical Center, Durham, NC. · Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills, CA. · Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain. · ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada. · Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. · Sanofi, Clinical Development, R&D, Montpellier, France. · Sanofi, Chilly-Mazarin, France. · Regeneron Pharmaceuticals Inc, Tarrytown, NY. · Lipid Clinic, Point Médical, Dijon, France. · Pubmed 27625344
  • Point Médical, Dijon, France. Electronic address: · Baylor College of Medicine, Houston, TX, USA. · Radiant Research - Phoenix SE, Chandler, AZ, USA. · Università di Palermo - Policlinico "P. Giaccone", Palermo, Italy. · Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany. · University of Dundee, Dundee, Scotland. · Regeneron Pharmaceuticals, Inc. Tarrytown, NY, USA. · Sanofi, Paris, France. · Pubmed 26638010
  • CGH Medical Center, Sterling, Illinois; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: · Department of Pharmacological and Biomolecular Sciences, University of Milan and IRCCS Multimedica, Milan, Italy. · Lipid Clinic, Point Médical, Dijon, France. · Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey. · Pubmed 27756478
2015
  • a Lipid Clinic, Point Medical , Dijon , France. · Pubmed 26563849
  • Endocrinology and Nutrition, Hôpital Laënnec, Nantes, 44035, France. · Center for Heart and Vascular Care, University of North Carolina, Chapel Hill, NC, USA. · Merck & Co, Inc., Kenilworth, NJ, USA. · Merck & Co, Inc., Kenilworth, NJ, USA. · MSD Inc., Brussels, Belgium. · Merck & Co, Inc., Kenilworth, NJ, USA. · Merck & Co, Inc., Kenilworth, NJ, USA. · Point Medical, 21000, Dijon, France. · Pubmed 25985907
2013
2011
  • Point Medical, Rond Point de la Nation, 21000 Dijon, France. Electronic address: · Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA. · Pubmed 21600523
2009
Probable:    University of Dijon      
2017
  • a Department of Cardiology , CHU Dijon Bourgogne and Point Medical , Dijon , France. · Pubmed 29171769
  • Lipid Clinic, Point Médical, Dijon, France; Department of Cardiology, CHU Dijon Bourgogne, Dijon, France. Electronic address: · University of Edinburgh, Edinburgh, UK. · Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. · Sanofi, Bridgewater, NJ, USA. · Sanofi, Chilly-Mazarin, France. · University of Iowa, Iowa City, IA, USA. · Pubmed 28693998
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 24 total) written by Michel Farnier about Hypercholesterolemia:

  • Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. 2017
  • Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. 2017
  • Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. 2017
  • Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. 2016
  • Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. 2016
  • Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. 2016
  • An evaluation of alirocumab for the treatment of hypercholesterolemia. 2015
  • Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. 2015
  • Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. 2015
  • Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. 2014
Show List of Full Article Records
Google Searches

Learn more about Michel Farnier using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
Miscellaneous institutions in Dijon
University of Dijon
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
Miscellaneous institutions in Dijon
2017
  • University of Iowa, Iowa City, Iowa. Electronic address: · Icahn School of Medicine at Mount Sinai, New York, New York. · Point Médical, Dijon, France. · Sanofi, Bridgewater, New Jersey. · Regeneron Pharmaceuticals, Inc., Tarrytown, New York. · Sanofi, Chilly-Mazarin, France. · Regeneron Pharmaceuticals, Inc., Basking Ridge, New Jersey. · Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands. · Pubmed 28153102
2016
  • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands · Duke University Medical Center, Durham, NC. · Westside Medical Associates of Los Angeles Cedars-Sinai Heart Institute, Beverly Hills, CA. · Lipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain. · ECOGENE-21 Clinical and Translational Research Center and Department of Medicine, Université de Montréal, Chicoutimi, Quebec, Canada. · Lipid Disorders Clinic, Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. · Sanofi, Clinical Development, R&D, Montpellier, France. · Sanofi, Chilly-Mazarin, France. · Regeneron Pharmaceuticals Inc, Tarrytown, NY. · Lipid Clinic, Point Médical, Dijon, France. · Pubmed 27625344
  • Point Médical, Dijon, France. Electronic address: · Baylor College of Medicine, Houston, TX, USA. · Radiant Research - Phoenix SE, Chandler, AZ, USA. · Università di Palermo - Policlinico "P. Giaccone", Palermo, Italy. · Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany. · University of Dundee, Dundee, Scotland. · Regeneron Pharmaceuticals, Inc. Tarrytown, NY, USA. · Sanofi, Paris, France. · Pubmed 26638010
  • CGH Medical Center, Sterling, Illinois; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: · Department of Pharmacological and Biomolecular Sciences, University of Milan and IRCCS Multimedica, Milan, Italy. · Lipid Clinic, Point Médical, Dijon, France. · Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey. · Pubmed 27756478
2015
  • a Lipid Clinic, Point Medical , Dijon , France. · Pubmed 26563849
  • Endocrinology and Nutrition, Hôpital Laënnec, Nantes, 44035, France. · Center for Heart and Vascular Care, University of North Carolina, Chapel Hill, NC, USA. · Merck & Co, Inc., Kenilworth, NJ, USA. · Merck & Co, Inc., Kenilworth, NJ, USA. · MSD Inc., Brussels, Belgium. · Merck & Co, Inc., Kenilworth, NJ, USA. · Merck & Co, Inc., Kenilworth, NJ, USA. · Point Medical, 21000, Dijon, France. · Pubmed 25985907
2013
2011
  • Point Medical, Rond Point de la Nation, 21000 Dijon, France. Electronic address: · Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA. · Pubmed 21600523
2009
University of Dijon
2017
  • a Department of Cardiology , CHU Dijon Bourgogne and Point Medical , Dijon , France. · Pubmed 29171769
  • Lipid Clinic, Point Médical, Dijon, France; Department of Cardiology, CHU Dijon Bourgogne, Dijon, France. Electronic address: · University of Edinburgh, Edinburgh, UK. · Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. · Sanofi, Bridgewater, NJ, USA. · Sanofi, Chilly-Mazarin, France. · University of Iowa, Iowa City, IA, USA. · Pubmed 28693998
18 Other Locations Show
Yearly article counts 03331217121
 
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.